238 related articles for article (PubMed ID: 32463296)
1. Antibody-drug conjugates for the treatment of ovarian cancer.
Calo CA; O'Malley DM
Expert Opin Biol Ther; 2021 Jul; 21(7):875-887. PubMed ID: 32463296
[TBL] [Abstract][Full Text] [Related]
2. Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer.
Porter RL; Matulonis UA
Expert Rev Anticancer Ther; 2023; 23(8):783-796. PubMed ID: 37458180
[TBL] [Abstract][Full Text] [Related]
3. Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations.
Nwabufo CK
Cancer Chemother Pharmacol; 2024 Feb; 93(2):89-105. PubMed ID: 37594572
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gilbert L; Oaknin A; Matulonis UA; Mantia-Smaldone GM; Lim PC; Castro CM; Provencher D; Memarzadeh S; Method M; Wang J; Moore KN; O'Malley DM
Gynecol Oncol; 2023 Mar; 170():241-247. PubMed ID: 36736157
[TBL] [Abstract][Full Text] [Related]
5. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
Moore KN; O'Malley DM; Vergote I; Martin LP; Gonzalez-Martin A; Malek K; Birrer MJ
Gynecol Oncol; 2018 Oct; 151(1):46-52. PubMed ID: 30093227
[TBL] [Abstract][Full Text] [Related]
6. Antibody-Drug Conjugates in Gynecologic Cancers.
Anastasio MK; Shuey S; Davidson BA
Curr Treat Options Oncol; 2024 Jan; 25(1):1-19. PubMed ID: 38172449
[TBL] [Abstract][Full Text] [Related]
7. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
O'Malley DM; Matulonis UA; Birrer MJ; Castro CM; Gilbert L; Vergote I; Martin LP; Mantia-Smaldone GM; Martin AG; Bratos R; Penson RT; Malek K; Moore KN
Gynecol Oncol; 2020 May; 157(2):379-385. PubMed ID: 32081463
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates for ovarian cancer: current clinical development.
Stewart D; Cristea M
Curr Opin Obstet Gynecol; 2019 Feb; 31(1):18-23. PubMed ID: 30531606
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FRa positive expression: A systematic review and meta-analysis.
Wang Y; Liu L; Jin X; Yu Y
Crit Rev Oncol Hematol; 2024 Feb; 194():104230. PubMed ID: 38122916
[TBL] [Abstract][Full Text] [Related]
10. Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer.
Gonzalez-Ochoa E; Veneziani AC; Oza AM
Clin Med Insights Oncol; 2023; 17():11795549231187264. PubMed ID: 37528890
[TBL] [Abstract][Full Text] [Related]
11. FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.
Moore KN; Vergote I; Oaknin A; Colombo N; Banerjee S; Oza A; Pautier P; Malek K; Birrer MJ
Future Oncol; 2018 Jul; 14(17):1669-1678. PubMed ID: 29424243
[TBL] [Abstract][Full Text] [Related]
12. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.
Moore KN; Martin LP; O'Malley DM; Matulonis UA; Konner JA; Vergote I; Ponte JF; Birrer MJ
Future Oncol; 2018 Jan; 14(2):123-136. PubMed ID: 29098867
[TBL] [Abstract][Full Text] [Related]
13. Mirvetuximab soravtansine: A breakthrough in targeted therapy for platinum-resistant ovarian cancer.
Kokori E; Olatunji G; Komolafe R; Abraham IC; Ukoaka B; Samuel O; Ayodeji A; Ogunbowale I; Ezenwoba C; Aderinto N
Medicine (Baltimore); 2024 May; 103(20):e38132. PubMed ID: 38758856
[TBL] [Abstract][Full Text] [Related]
14. Advances in antibody-drug conjugates for gynecologic malignancies.
Tymon-Rosario J; Gorman M; Richardson DL; Washington C; Santin AD
Curr Opin Obstet Gynecol; 2023 Feb; 35(1):6-14. PubMed ID: 36484278
[TBL] [Abstract][Full Text] [Related]
15. Revisiting antibody-drug conjugates and their predictive biomarkers in platinum-resistant ovarian cancer.
El Bairi K; Al Jarroudi O; Afqir S
Semin Cancer Biol; 2021 Dec; 77():42-55. PubMed ID: 33812984
[TBL] [Abstract][Full Text] [Related]
16. The evolving landscape of antibody-drug conjugates in gynecologic cancers.
Tolcher A; Hamilton E; Coleman RL
Cancer Treat Rev; 2023 May; 116():102546. PubMed ID: 37023499
[TBL] [Abstract][Full Text] [Related]
17. Mirvetuximab Soravtansine: First Approval.
Heo YA
Drugs; 2023 Feb; 83(3):265-273. PubMed ID: 36656533
[TBL] [Abstract][Full Text] [Related]
18. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
Moore KN; Martin LP; O'Malley DM; Matulonis UA; Konner JA; Perez RP; Bauer TM; Ruiz-Soto R; Birrer MJ
J Clin Oncol; 2017 Apr; 35(10):1112-1118. PubMed ID: 28029313
[TBL] [Abstract][Full Text] [Related]
19. Integrating antibody drug conjugates in the management of gynecologic cancers.
Chelariu-Raicu A; Mahner S; Moore KN; Lorusso D; Coleman RL
Int J Gynecol Cancer; 2023 Mar; 33(3):420-429. PubMed ID: 36878560
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine.
Matulonis UA; Birrer MJ; O'Malley DM; Moore KN; Konner J; Gilbert L; Martin LP; Bauer TM; Oza AM; Malek K; Pinkas J; Kim SK
Clin Cancer Res; 2019 Mar; 25(6):1727-1736. PubMed ID: 30413525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
